Monica Welling is a distinguished Co-founder and Managing Director at Atheln, Inc., where she leverages over 25 years of extensive experience in the biopharmaceutical sector to drive innovation and strategic growth. Under her leadership, Atheln has emerged as a pioneering interim management and consulting group,...
Monica Welling is a distinguished Co-founder and Managing Director at Atheln, Inc., where she leverages over 25 years of extensive experience in the biopharmaceutical sector to drive innovation and strategic growth. Under her leadership, Atheln has emerged as a pioneering interim management and consulting group, specializing in the creation and implementation of robust product development and commercialization strategies tailored for start-up and mid-sized biopharma companies. Monica’s unique approach integrates commercial and technical disciplines, ensuring that clients maximize product value while navigating the complexities of drug development and regulatory affairs.
Throughout her tenure at Atheln, Monica has successfully collaborated with over 85 companies on more than 90 projects, demonstrating her exceptional ability to build and manage organizations that achieve critical milestones for value creation. Her expertise spans various therapeutic areas, with a particular focus on immunology, where she has spearheaded numerous product launches and strategic alliances. Monica’s deep understanding of market analysis and research enables her to identify emerging trends and opportunities, positioning her clients for success in a competitive landscape.
Monica is not only a decisive leader but also a mentor to many in the industry, fostering a culture of collaboration and innovation. Her commitment to excellence in program management and her comprehensive knowledge of pharmaceutics and drug development have made her a sought-after expert in the biopharma community. As Atheln continues to grow, Monica remains dedicated to empowering her clients to navigate the challenges of the biopharmaceutical landscape, ensuring they achieve their strategic objectives and deliver value to prescribers, payers, and patients alike.
